Advertisement

Experiences with Human Calcitonin in the Treatment of Paget’s Disease of Bone

  • John G. Haddad

Abstract

With the discovery of the hormone calcitonin 28 years ago, increasing interest was centered on its composition, secretion, and mechanisms of action.1–5 Eventually, the porcine, human, and salmon calcitonins were sequenced and synthesized,2,3,6 and growing enthusiasm for their anti-bone resorption effect led to many clinical investigations of their influences on disorders of mineral and skeletal homeostasis. The hormone’s physiologic role is still not clearly understood. However, its interference with some portions of osteolytic mechanisms has been repeatedly observed to lead to beneficial effects on bone turnover and skeletal remodeling. Since this interference is most rapidly and clearly seen in conditions of accelerated bone turnover, many of the hormone’s convincing effects have been appreciated in patients with Paget’s bone disease. 7–10

Keywords

Bone Turnover Salmon Calcitonin Human Calcitonin Skeletal Homeostasis Calcitonin Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rittel W, Brugger M, Kamber B, et al: Thyrocalcitonins: III. Synthesis des alpha-thyro-calcitonins. Helv Chim Acta 1968; 51: 924–928.PubMedCrossRefGoogle Scholar
  2. 2.
    Neher R, Riniker B, Rittel W, Zuber H: Menschliches Calcitonin: III. Struktur von Calcitonin M and D. Helv Chim Acta 1968; 51: 1900–1905.PubMedCrossRefGoogle Scholar
  3. 3.
    Niall HD, Keutmann HT, Copp DH, Potts JT Jr Amino acid sequence of salmon ultimo-branchial calcitonin. Proc Natl Acad Sci USA 1969; 64: 771–775.PubMedCrossRefGoogle Scholar
  4. 4.
    Martin TJ: Actions of calcitonin and mithramycin. Arthritis Rheum 1980; 23: 1131–1138.PubMedCrossRefGoogle Scholar
  5. 5.
    Maclntyre I, Evans IMA, Hobitz HHG, et al: Chemistry, physiology and therapeutic applications of calcitonin. Arthritis Rheum 1980, 23: 1139–1147.CrossRefGoogle Scholar
  6. 6.
    Kahnt FW, Riniker B, Maclntyre I, Weher R: Thyrocalcitonin: l. Isolierung und Charakterisierung wirksamer peptide aus schwineschilddrusen. Heb Chim Acta 1968; 51: 214–219.CrossRefGoogle Scholar
  7. 7.
    Evans IMA: Human calcitonin in the treatment of Paget’s disease: Long-term trials, in Maclntyre I (ed): Human Calcitonin and Paget’s Disease. Bern, Stuttgart, Vienna, Hans Huber Publishers, 1977, pp 111–123.Google Scholar
  8. 8.
    Burckhardt P, Ducommun J, Hessler C: Treatment of Paget’s disease with human calcitonin, in Maclntyre (ed): Human Calcitonin and Paget’s Disease. Bern, Stuttgart, Vienna, Hans Huber Publishers, 1977, pp 155–166.Google Scholar
  9. 9.
    Ziegler R, Holz G, Rave F, et al: Therapeutic studies with human calcitonin, in Maclntyre (ed): Human Calcitonin and Paget’s Disease. Bern, Stuttgart, Vienna, Hans Huber Publishers, 1977, pp 167–178.Google Scholar
  10. 10.
    Nagant de Deuxchaisnes C: Calcitonin in the treatment of Paget’s disease. Triangle 1983; 22: 103–128.Google Scholar
  11. 11.
    Singer FR, Rude RK, Mills BG: Studies of the treatment and etiology of Paget’s disease of bone, in Maclntyre I (ed): Human Calcitonin and Paget’s Disease. Bern, Stuttgart, Vienna, Hans Huber Publishers, 1977, pp 93–110.Google Scholar
  12. 12.
    Haddad JG: Effective human calcitonin therapy following immunological resistance to salmon calcitonin therapy in Paget’s bone disease, in MacIntyre (ed): Human Calcitonin and Paget’s Disease. Bern, Stuttgart, Vienna, Hans Huber Publishers, 1977, pp 195–206.Google Scholar
  13. 13.
    Lang R, Milkman M, Jensen PS, Vignery AMC: Chronic treatment of Paget’s disease of bone with synthetic human calcitonin. Yale J Biol 1981; 54: 355–365.PubMedGoogle Scholar
  14. 14.
    Rojanasathit S, Rosenberg E, Haddad JG: Paget’s bone disease: Response to human calcitonin in patients resistant to salmon calcitonin. Lancet 1974; 2: 1412–1415.PubMedCrossRefGoogle Scholar
  15. 15.
    Nuti R, Vattimo A: Synthetisches human-calcitonin hei osteodistrophia deformans (Paget) und Osteoporose. Dtsch Med Wochenschr 1981; 106: 149–152.PubMedCrossRefGoogle Scholar
  16. 16.
    Altman RD, Collins-Yudiskas B: Synthetic human calcitonin in refractory Paget’s disease of bone. Arch Intern Med 1987; 147: 1305–1308.PubMedCrossRefGoogle Scholar
  17. 17.
    Doyle RH, Pennock J, Greenberg P, et al: Radiological evidence of a dose-related response to long-term treatment of Paget’s disease with human calcitonin. Br J Radiol 1974; 47: 1–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Murphy WA, Whyte MP, Haddad JG: Paget’s bone disease: Radiological documentation of healing with human calcitonin therapy. Radiology 1980; 136: 1–4.PubMedGoogle Scholar
  19. 19.
    Woodhouse NJY, Maclntyre L, Joplin GF, Doyle FH: Radiological regression in Paget’s disease treated by human calcitonin. Lancet 1972; 2: 992–994.PubMedCrossRefGoogle Scholar
  20. 20.
    Nagant, de Deuxchaisnes C, Maldague B, Malghem J et al: The action of the main therapeutic regimes on Paget’s disease of bone, with a note on the effect of vitamin D deficiency. Arthritis Rheum 1980; 23: 1215–1234.CrossRefGoogle Scholar
  21. 21.
    Haddad JG, Caldwell JG: Calcitonin resistance: Clinical and immunological studies in subjects with Paget’s disease of bone treated with porcine and salmon calcitonin. J Clin Invest 1972; 51: 3133–3341.PubMedCrossRefGoogle Scholar
  22. 22.
    Singer FR, Fredericks RS, Minkin C: Salmon calcitonin therapy for Paget’s disease of bone: The problem of acquired clinical resistance. Arthritis Rheum 1980; 23: 1148–1154.PubMedCrossRefGoogle Scholar
  23. 23.
    Nagant de Deuxchaisnes C: Calcitonin in the treatment of Paget’s disease. Triangle 1983; 22: 103–128.Google Scholar
  24. 24.
    Dietrich FM, Fischer JA, Bijvoet OLM: Formation of antibodies to synthetic human calcitonin during treatment of Paget’s disease. Acta Endocrinol 1979; 92: 468–476.PubMedGoogle Scholar

Copyright information

© Elsevier Science Publishing Co., Inc. 1991

Authors and Affiliations

  • John G. Haddad

There are no affiliations available

Personalised recommendations